Module

Monoclonal Antibodies in Lymphoproliferative Disorders: From Rationale to Results

Source: Advances in Lymphoproliferative Disease: From Molecular Pathogenesis to Multitargeted Treatment

Monoclonal Antibodies in Lymphoproliferative Disorders: From Rationale to Results


Program Director: Alexandra M. Levine, MD

Faculty:

Jonathan W. Friedberg, MD
  • Jonathan W. Friedberg, MD

CME CREDIT INFORMATION

Release Date: 08/28/08

Expiration Date: 08/27/09


Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Registered Nurses: 0.8 Nursing CE credits

Status: Please log in to view status

Begin the Module

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the use of rituximab alone and in combination with chemotherapy for the treatment of non-Hodgkin’s lymphomas
  • Cite novel antibodies in clinical development for the treatment of non-Hodgkin’s lymphomas
  • Explain differences between the treatment of patients with and without previous treatment for non-Hodgkin’s lymphomas

Topics covered include:

  • Current Treatment Approaches in FL
  • Rituximab-Refractory/Resistant Disease
  • Novel Antibody-Based Therapies for FL
  • Conclusions
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grants provided by:

Educational grants support only the CME-certified components of this program.